ValuEngine cut shares of Audentes Therapeutics (NASDAQ:BOLD) from a buy rating to a hold rating in a research note published on Friday.

Other equities research analysts have also issued research reports about the stock. HC Wainwright set a $40.00 price objective on shares of Audentes Therapeutics and gave the company a buy rating in a report on Wednesday, August 8th. Mizuho raised shares of Audentes Therapeutics from a neutral rating to a buy rating and set a $26.00 price objective for the company in a report on Wednesday, August 8th. William Blair reissued a buy rating on shares of Audentes Therapeutics in a report on Tuesday, August 7th. Zacks Investment Research raised shares of Audentes Therapeutics from a hold rating to a buy rating and set a $44.00 price objective for the company in a report on Tuesday, July 10th. Finally, BidaskClub raised shares of Audentes Therapeutics from a hold rating to a buy rating in a report on Tuesday, September 18th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $35.45.

Shares of BOLD traded up $0.56 during mid-day trading on Friday, reaching $27.69. The stock had a trading volume of 1,699,736 shares, compared to its average volume of 424,443. Audentes Therapeutics has a 52-week low of $24.51 and a 52-week high of $46.18. The firm has a market capitalization of $1.48 billion, a P/E ratio of -8.14 and a beta of 0.73.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.07). As a group, equities analysts anticipate that Audentes Therapeutics will post -3.33 EPS for the current year.

In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 21,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $38.16, for a total value of $801,360.00. Following the transaction, the chief executive officer now owns 17,144 shares of the company’s stock, valued at $654,215.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew R. Patterson sold 12,952 shares of the company’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $40.00, for a total transaction of $518,080.00. Following the completion of the transaction, the chief executive officer now directly owns 12,952 shares in the company, valued at approximately $518,080. The disclosure for this sale can be found here. Insiders sold 77,039 shares of company stock worth $2,925,260 in the last ninety days. 6.60% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of BOLD. Wells Fargo & Company MN lifted its position in Audentes Therapeutics by 803.8% in the first quarter. Wells Fargo & Company MN now owns 307,537 shares of the biotechnology company’s stock valued at $9,242,000 after buying an additional 273,511 shares during the last quarter. Swiss National Bank lifted its position in shares of Audentes Therapeutics by 31.3% during the first quarter. Swiss National Bank now owns 43,600 shares of the biotechnology company’s stock worth $1,310,000 after purchasing an additional 10,400 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Audentes Therapeutics by 31.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 45,597 shares of the biotechnology company’s stock worth $1,371,000 after purchasing an additional 11,000 shares in the last quarter. American International Group Inc. lifted its position in shares of Audentes Therapeutics by 15.9% during the first quarter. American International Group Inc. now owns 12,829 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 1,761 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Audentes Therapeutics by 21.5% during the first quarter. Northern Trust Corp now owns 248,969 shares of the biotechnology company’s stock worth $7,482,000 after purchasing an additional 44,102 shares in the last quarter. 96.74% of the stock is currently owned by institutional investors.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Further Reading: How analysts view the yield curve

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.